Geneos Therapeutics is a technology company.
Geneos Therapeutics has raised $17.0M across 2 funding rounds.
Geneos Therapeutics has raised $17.0M in total across 2 funding rounds.
Geneos Therapeutics has raised $17.0M in total across 2 funding rounds.
Geneos Therapeutics's investors include 3B Future Health Ventures (Helsinn Investment Fund), Seventure Partners, Korea Investment Partners.
Geneos Therapeutics is a clinical-stage biotherapeutics company developing personalized immunotherapies for cancer (PICs) using its proprietary GT-EPIC™ platform. It creates custom DNA plasmids encoding up to 40 patient-specific tumor neoantigens, administered intradermally with a cytokine adjuvant (pIL-12) and electroporation to generate tumor-infiltrating lymphocytes (TILs) that target and potentially eradicate cancer cells.[1][2][4] The company serves cancer patients, particularly those with hepatocellular carcinoma (HCC) and glioblastoma (GBM), addressing the problem of tumor heterogeneity and immune evasion by including all targetable neoantigens rather than pre-selecting them, enabling broad applicability across solid tumors.[2][4] Geneos has raised $45.6M total funding, including a $45.5M recent round and $17M Series A2 in 2023 to expand its Phase Ib/IIa HCC trial, with a Phase 2b HCC trial in planning; notable momentum includes five-year recurrence-free survival in aggressive brain and liver cancer patients treated as monotherapy.[1][2][3][5]
Founded in 2016 (with some sources noting 2017) in Plymouth Meeting, Pennsylvania, Geneos Therapeutics emerged from expertise in DNA-based immunotherapies, led by Niranjan Y. Sardesai, Founder, President, CEO, and Director.[1][3][6] Sardesai and the team, including COO James A. Barlow and VP of Operations and Business Development James A. Barlow, built on multi-year optimizations in neoantigen targeting and immune programming.[1][3][4] Early traction came through clinical development in HCC and GBM, culminating in a $5M Series A3 extension in 2023 from Shanghai-based SHC to complete the GT-30 trial of its personalized cancer vaccine, alongside prior rounds like $17M Series A2.[1][5] Pivotal moments include durable five-year survival data in advanced patients, validating the GT-EPIC platform's holistic approach.[3][4]
Geneos stands out in personalized cancer immunotherapy through its GT-EPIC™ platform, emphasizing high neoantigen capacity, immunogenicity, and immune system orchestration:
Geneos rides the neoantigen-targeted cancer vaccine wave, a booming sector projected through 2030 amid advances in sequencing, AI-driven epitope prediction, and immunotherapy (e.g., mRNA vaccines like those from Moderna/BioNTech).[2][3][4] Timing is ideal post-checkpoint inhibitors' limitations in "cold" tumors, where Geneos' multi-neoantigen, DNA-based approach overcomes heterogeneity and low immunogenicity—key market forces favoring combination therapies and personalized medicine.[2][4] It influences the ecosystem by pioneering *non-selective* neoantigen inclusion, potentially setting standards for TIL therapies and expanding to Wnt-related cancers via patents, while contributing to industry analyses on durable responses in hard-to-treat solid tumors like HCC/GBM.[3][4]
Geneos is poised for Phase 2b advancement in HCC, with expansion to other indications leveraging its versatile GT-EPIC platform and recent funding momentum.[1][2][5] Trends like AI-optimized neoantigen analytics, combo regimens with PD-1 inhibitors, and regulatory tailwinds for personalized therapies will accelerate its path, potentially yielding registrational data by late 2020s.[3] Its influence may grow as a leader in scalable, high-capacity DNA immunotherapies, proving that *exquisitely personalized* treatments can deliver recurrence-free survival—one patient at a time, transforming clinical-stage promise into a cornerstone of cancer care.[2][3][4]
Geneos Therapeutics has raised $17.0M across 2 funding rounds. Most recently, it raised $5.0M Series A in April 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2023 | $5.0M Series A | 3B Future Health Ventures (Helsinn Investment Fund), Seventure Partners | |
| Mar 1, 2021 | $12.0M Series A | Korea Investment Partners |